https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54124 Wed 28 Feb 2024 15:15:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45084 Wed 26 Oct 2022 14:04:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47738 Wed 25 Jan 2023 15:08:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31116 Wed 24 Nov 2021 15:52:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36471 Wed 17 Nov 2021 16:29:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21399 Wed 11 Apr 2018 15:17:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29691 n = 39), rivaroxaban, (n = 56) or apixaban levels (n = 22) between February 2013 and November 2015 were analysed and compared to two different commercial drug specific calibrators from different manufacturers for each DOAC. Our results show that dabigatran (Hyphen and Technoclone) and rivaroxaban (Stago) calibrators tend to overestimate the APTT but are similar to patient samples for PT. A cut-off DOAC level of 50 ng/mL based on results from patient samples within the laboratory can be used as the lower limit which will result in prolongation of APTT for dabigatran (sensitivity 96%, n = 25) and PT for rivaroxaban (sensitivity 97%, n = 29), respectively. Individual laboratories should be familiar with the sensitivity of their coagulation reagents to different DOACs including differences between patient samples versus different commercial drug specific calibrators.]]> Wed 11 Apr 2018 15:02:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31416 28 days) received in the main laboratory rotated from peripheral hospitals, down from 6%-41% to 0%-2.5%. Conclusion: Age-related expiry of blood products is preventable and can be significantly reduced by improving practices in the pathology service. This study provides proof of principle for "zero tolerance for RBC unit expiry" across a large networked blood banking service.]]> Wed 11 Apr 2018 10:55:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55100 Wed 10 Apr 2024 08:45:11 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41430 Wed 03 Aug 2022 14:12:29 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29675 Wed 02 Mar 2022 14:26:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36679 Thrombosis Research, Vol. 179, p. 28-30.]]> Tue 23 Jun 2020 15:03:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37665 2 ≥ 0.997). However, TruCount beads produced the most consistent (concentration variation = 3.8%) calculated numbers of plasma CD41⁺/Annexin V⁺ MV, which were significantly higher from that calculated using either Flow-Count or CountBright (p < 0.001). The FACSCanto was able to resolve 0.5 μm beads by FSC and 0.16 μm beads by SSC, but there were significantly more background events using SSC compared with FSC (3113 vs. 470; p = 0.008). In general, sample analysis by SSC resulted in significantly higher numbers of MV (p < 0.0001) but was well correlated with enumeration by FSC for all MV subtypes (ρ = 0.62–0.89, p < 0.0001). We conclude that all counting beads provided linear results at concentrations ranging from 6 beads/μl to 100 beads/μl, but TruCount was the most consistent. Using SSC to gate MV events produced high background which negatively affected counting bead enumeration and overall MV calculations. Strategies to reduce SSC background should be employed in order to reliably use this technique.]]> Tue 09 Mar 2021 18:12:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42910 Tue 06 Sep 2022 15:49:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34451 Tue 03 Sep 2019 18:26:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34050 Thu 28 Oct 2021 13:03:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27912 in vitro and mouse models of AML are promising; however, its safety for use in AML has not been assessed. From human studies of fingolimod in other indications, it is possible to evaluate whether the safety and toxicity profile of the PP2A activators will allow their use in treating AML. A literature review was carried out to assess safety before the commencement of Phase I trials of the PP2A activator Fingolimod in AML. From human studies of fingolimod in other indications, it is possible to evaluate whether the safety and toxicity profile of the PP2A activators will allow their use in treating AML. A systematic review of published literature in Medline, EMBASE and the Cochrane Library of critical reviews was carried out. International standards for the design and reporting of search strategies were followed. Search terms and medical subject headings used in trials involving PP2A activators as well as a specific search were performed for 'adverse events','serious adverse events', 'delays in treatment', ' side effects' and 'toxicity' for primary objectives. Database searches were limited to papers published in the last 12 years and available in English. The search yielded 677 articles. A total of 69 journal articles were identified as relevant and included 30 clinical trials, 24 review articles and 15 case reports. The most frequently reported adverse events were nausea, diarrhoea, fatigue, back pain, influenza viral infections, nasopharyngitis and bronchitis. Specific safety concerns include monitoring of the heart rate and conduction at commencement of treatment as cardiotoxicity has been reported. There is little evidence to suggest specific bone marrow toxicity. Lymophopenia is a desired effect in the management of multiple sclerosis, but may have implications in patients with acute leukaemia as it may potentially increase susceptibility to viral infections such as influenza. Fingolimod is a potential treatment option for AML with an acceptable risk to benefit ratio, given its lack of bone marrow toxicity and the relatively low rate of serious side effects. As most patients with AML are elderly, specific monitoring for cardiac toxicity as well as infection would be required.]]> Thu 28 Oct 2021 13:02:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50338 .8) for most normal cell types and did not require any manual reassignment. The AI digital differential was less reliable for abnormal blood films (r = .50-.87), but could be greatly improved by manual assessment of digital images for most cell types (r > .95) with the exception of immature granulocytes (r = .62). For blast identification, initial AI digital differentials showed 96% sensitivity and 25% specificity, which was improved to 99% and 84%, respectively, after manual digital review.Conclusions: The Techcyte platform allowed remote viewing and manual analysis of digitized slides that was comparable to microscopy. The AI software produced adequate WBC differentials for normal films and had high sensitivity for blast identification in malignant films.]]> Thu 20 Jul 2023 11:18:11 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44081 Thu 06 Oct 2022 15:06:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:9688 Sat 24 Mar 2018 08:39:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5366 Sat 24 Mar 2018 07:43:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27930 s, was -0.34 and -0.30 respectively, p<0.05) and positively correlated with the ELISA MP-activity assay (r_s=0.42 for both, p<0.05). In addition, endothelial MV levels weakly correlated with white cell counts (r_s = 0.27, p<0.05). Conclusions Thrombin generation and flow cytometry for phosphatidylserine or tissue factor expressing MV correlate well as markers for procoagulant activity. A combination of optical or non-optical enumeration as well as functional methods may be required for a complete profiling of circulating MV.]]> Sat 24 Mar 2018 07:36:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50787 Sat 05 Aug 2023 11:22:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35414 Mon 29 Jul 2019 11:13:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34877 Mon 23 Sep 2019 12:38:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42366 Mon 22 Aug 2022 14:08:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42359 Mon 22 Aug 2022 14:08:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47968 Mon 13 Feb 2023 15:58:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54765 Mon 11 Mar 2024 15:01:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52306 Mon 09 Oct 2023 10:16:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45844 20 x 109/L, and avoidance of severe bleeding. Steroids are the standard first line treatment, with either 6-week courses of tapering prednisone or repeated courses of high dose dexamethasone providing equivalent efficacy. Intravenous immunoglobulin can be used periprocedurally or as first line therapy in combination with steroids. Changes in management as a result of this statement: There is no consensus on choice of second line treatments. Options with the most robust evidence include splenectomy, rituximab and thrombopoietin receptor agonists. Other therapies include azathioprine, mycophenolate mofetil, dapsone and vinca alkaloids. Given that up to one-third of patients achieve a satisfactory haemostatic response, splenectomy should be delayed for at least 12 months if possible. In life-threatening bleeding, we recommend platelet transfusions to achieve haemostasis, along with intravenous immunoglobulin and high dose steroids.]]> Mon 07 Nov 2022 14:17:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46592 n = 33). SNP-microarray analysis identified additional aberrations in 97% of patients (32/33) compared to conventional techniques. This changed the genomic risk category of 24% (8/33) of patients. Additionally, 27% (9/33) of patients exhibited a ‘hyperdiploid’ genome, which is generally associated with a good genomic risk and favourable outcomes. An enrichment of IKZF1 deletions was observed with one third of the cohort affected. Our findings suggest the current classification system could be improved and highlights the need to use more sensitive techniques such as SNP-microarray for cytogenomic risk stratification in B-ALL.]]> Fri 25 Nov 2022 15:04:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51900 Fri 22 Sep 2023 09:29:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48457 3000 deaths prevented under high transmission. Risks versus benefits varied significantly between age groups and transmission levels. Under high transmission, deaths prevented by AZ vaccine far exceed deaths from TTS (by 8 to > 4500 times depending on age). Probability of dying from COVID-related atypical severe blood clots was 58–126 times higher (depending on age and sex) than dying from TTS. To our knowledge, this is the first example of the use of Bayesian networks for risk–benefit analysis for a COVID-19 vaccine. The model can be rapidly updated to incorporate new data, adapted for other countries, extended to other outcomes (e.g., severe disease), or used for other vaccines.]]> Fri 17 Mar 2023 12:07:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54830 Fri 15 Mar 2024 11:53:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44495 Fri 14 Oct 2022 09:46:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51529 Fri 08 Sep 2023 12:10:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39994 Fri 01 Jul 2022 13:35:31 AEST ]]>